Adjuvant chemotherapy for primary breast cancer

Jemal A, Tiwari RC, Murray T, et al.: Cancer Statistics 2004. CA Cancer J Clin 2004, 54:8–29.

Olivotto IA, Bajdik C, Ravdin PM, et al.: An independent population-based validation of the adjuvant decision-aid for stage I–II breast cancer [abstract]. Proc ASCO 2004, 23:7.

Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998, 352:930–942.

Crivellari D, Bonetti M, Castiglione-Gertsch M, et al.: Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000, 18:1412–1422.

Abrams JS: A review of the National Institutes of Health (NIH) Consensus Development Conference on Adjuvant Therapy of Breast Cancer. Breast 2001, 10(Suppl 1):S10.

Fisher B, Brown A, Dimitrov N, et al.: Two months of doxorubicin-cyclophosphamide with and without interval re-induction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive-node breast cancer patients with tamoxifen-non-responsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990, 8:1483–1496.

Levine MN, Bramwell VH, Pritchard KI, et al.: Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with nodepositive breast cancer. J Clin Oncol 1998, 16:2651–2658.

Mourisden H, Andersen J, Andersson M, et al.: Adjuvant anthracycline in breast cancer: improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin [abstract]. Proc ASCO 1999, 18:68a.

Gusterson BA, Gelber RD, Goldhirsch A, et al.: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992, 10:1049–1056.

Menard S, Valagussa P, Pilotti S, et al.: Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001, 19:329–335.

Thor AD, Berry DA, Budman DR, et al.: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998, 90:1346–1360.

Henderson IC, Berry DA, Demetri GD, et al.: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976–983. A pivotal clinical trial that reported a benefit for adding taxanes to AC sequentially in the adjuvant setting.

Mamounas EP, Bryant J, Lembersky BC, et al.: Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer [abstract]. Proc ASCO 2003, 22:4.

Nabholtz JM, Pienkowski T, Mackey J, et al.: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 001 study [abstract]. Proc ASCO 2002, 21:36a.

Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1994, 4:1162–1170.

Wood W, Budman D, Korzun A, et al.: Dose and dose intensity trial of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994, 330:1253–1259.

Fisher B, Anderson S, Wickerman DL, et al.: Increased intensification and total dose of cyclophosphamide in a doxorubicincyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B22. J Clin Oncol 1997, 15:1858–1869.

Fisher B, Anderson S, DeCillis A, et al.: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel project B-25. J Clin Oncol 1999, 17:3374–3388.

Rodenhuis S, Bontenbal M, Beex LV, et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003, 349:7–16.

Norton L: A Gompertzian model of human breast cancer growth. Cancer Res 1988, 7067–7071.

Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more tan three positive nodes. JAMA 1995, 273:542–547.

Surbone A, Gilewski T, Dang CT, Norton L: Cytokinetics. In Cancer Medicine, edn 5. Edited by Holland JF, Frei E, Bast RC, et al. Baltimore: Williams & Wilkins; 2000:491–519.

Hudis C, Seidman A, Baselga J, et al.: Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for respectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 1999, 17:93–100.

Hudis C, Fornier M, Riccio L, et al.: 5-year result of dose-intensive sequential adjuvant chemotherapy for women with highrisk node-positive breast cancer: a phase II study. J Clin Oncol 1999, 17:1118.

Citron ML, Berry DA, Cirrincione C, et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003, 21:1431–1439. This trial translated a mathematical concept into clinical practice, revealing a benefit for the "dose-dense" schedule of chemotherapy.

Ries LAG, Eisner MP, Hankey BF, et al.: SEER Cancer Statistics Review, 1973–1998. Bethesda, MD: National Cancer Institute; 2001.